This will be necessary to identify new biomarkers for susceptibility to TLR4 targeting strategies since the experience with MyD88/IRAK1 inhibition suggests that the antileukemic effect of this strategy is not associated with established prognostic factors for chemosensitivity in human AML [123]. The gene discussed is IRAK1; the disease is acute myeloid leukemia.